|
SPAG9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.77835524084458E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.47302178735254E-12 |
| Normal-vs-Stage2 |
2.621200E-04 |
| Normal-vs-Stage3 |
2.79619993825975E-10 |
| Normal-vs-Stage4 |
1.93522975422411E-12 |
| Stage1-vs-Stage2 |
9.436300E-02 |
| Stage1-vs-Stage3 |
5.035000E-01 |
| Stage1-vs-Stage4 |
2.738500E-02 |
| Stage2-vs-Stage3 |
6.787600E-02 |
| Stage2-vs-Stage4 |
7.164400E-03 |
| Stage3-vs-Stage4 |
2.065000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.4757973449141E-13 |
| Normal-vs-AfricanAmerican |
1.984400E-04 |
| Normal-vs-Asian |
1.51459955688438E-10 |
| Caucasian-vs-AfricanAmerican |
3.430000E-01 |
| Caucasian-vs-Asian |
2.896600E-01 |
| AfricanAmerican-vs-Asian |
1.036420E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.81600315183073E-11 |
| Normal-vs-Female |
2.72393219091782E-12 |
| Male-vs-Female |
4.667400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74560033094906E-10 |
| Normal-vs-Age(41-60Yrs) |
1.02939878843245E-12 |
| Normal-vs-Age(61-80Yrs) |
1.45930045825082E-10 |
| Normal-vs-Age(81-100Yrs) |
3.809200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.893200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.352200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.124200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.917400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.299400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.595200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.854400E-02 |
| Classical-VS-Follicular |
1.448970E-01 |
| Classical-VS-Other |
1.767830E-02 |
| Classical-VS-Normal |
1.99507077525141E-12 |
| Tall-VS-Follicular |
5.464500E-03 |
| Tall-VS-Other |
3.769400E-01 |
| Tall-VS-Normal |
2.59470223085145E-11 |
| Follicular-VS-Other |
2.882600E-03 |
| Follicular-VS-Normal |
3.74250000000353E-05 |
| Other-VS-Normal |
8.21360000013982E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.47899536640762E-11 |
| Normal-vs-N1 |
6.73920030891395E-10 |
| N0-vs-N1 |
2.155600E-01 |
|
|
